patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_757651 | REC_0004601 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 25 | 10.1 | 61 | female | 1 | 15 | 4.6 | 0 | sotorasib 960 mg daily | 39 | false | MSS | 2026-03-15T05:35:57.983976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435420 | REC_0004602 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 5.5 | 67 | female | 1 | 19 | 4.4 | 1 | pembrolizumab 200 mg q3w | 8.7 | false | MSS | 2026-03-15T05:35:57.984264+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124689 | REC_0004603 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 13 | 71 | female | 1 | 0 | 3 | 7 | entrectinib 600 mg daily | 9.6 | false | MSI-H | 2026-03-15T05:35:57.984641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580921 | REC_0004604 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 14.5 | 50 | female | 0 | 21 | 7.7 | 1 | sotorasib 960 mg daily | 28.2 | false | MSS | 2026-03-15T05:35:57.984883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928205 | REC_0004605 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 2.7 | 62 | female | 1 | 9 | 7 | 5 | pembrolizumab 200 mg q3w | 5.8 | false | MSS | 2026-03-15T05:35:57.985117+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732835 | REC_0004606 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 9 | 73 | female | 1 | 13 | 6.5 | 2 | alectinib 600 mg BID | 9.9 | true | MSS | 2026-03-15T05:35:57.985351+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_898839 | REC_0004607 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 13.3 | 52 | male | 0 | 30 | 4.6 | 1 | osimertinib 80 mg daily | 16.6 | false | MSS | 2026-03-15T05:35:57.985588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954276 | REC_0004608 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 8.4 | 66 | female | 1 | 21 | 5.3 | 6 | sotorasib 960 mg daily | 4.6 | false | MSS | 2026-03-15T05:35:57.985816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306238 | REC_0004609 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 3.6 | 60 | male | 0 | 50 | 5.8 | 8 | pembrolizumab 200 mg q3w | 13.2 | true | MSS | 2026-03-15T05:35:57.986050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732222 | REC_0004610 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.6 | 62 | male | 1 | 18 | 5.6 | 6 | sotorasib 960 mg daily | 4.3 | false | MSS | 2026-03-15T05:35:57.986285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332848 | REC_0004611 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 8.9 | 77 | female | 1 | 16 | 6.2 | 2 | sotorasib 960 mg daily | 20.2 | false | MSS | 2026-03-15T05:35:57.986517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879138 | REC_0004612 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 10.8 | 58 | male | 0 | 19 | 5.3 | 2 | osimertinib 80 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:35:57.986752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729322 | REC_0004613 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 12 | 75 | female | 0 | 14 | 3.4 | 7 | sotorasib 960 mg daily | 8 | true | MSS | 2026-03-15T05:35:57.986986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511561 | REC_0004614 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 10.5 | 73 | female | 2 | 9 | 5.6 | 1 | alectinib 600 mg BID | 27.2 | true | MSS | 2026-03-15T05:35:57.987216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489519 | REC_0004615 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 17.2 | 67 | female | 1 | 5 | 6.9 | 6 | osimertinib 80 mg daily | 7.4 | true | MSS | 2026-03-15T05:35:57.987452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_675367 | REC_0004616 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 15.7 | 60 | female | 1 | 16 | 3 | 4 | alectinib 600 mg BID | 15.7 | true | MSS | 2026-03-15T05:35:57.987735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449150 | REC_0004617 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 13.3 | 78 | female | 2 | 19 | 2 | 2 | sotorasib 960 mg daily | 17.7 | false | MSS | 2026-03-15T05:35:57.987970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748467 | REC_0004618 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 13.4 | 54 | male | 0 | 9 | 2.8 | 1 | entrectinib 600 mg daily | 26.7 | false | MSS | 2026-03-15T05:35:57.988260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818449 | REC_0004619 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 13.3 | 73 | female | 1 | 0 | 4.7 | 5 | osimertinib 80 mg daily | 15.8 | true | MSS | 2026-03-15T05:35:57.988513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162812 | REC_0004620 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 16.4 | 74 | female | 2 | 24 | 5 | 8 | entrectinib 600 mg daily | 18.6 | false | MSI-H | 2026-03-15T05:35:57.988748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796410 | REC_0004621 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 9.4 | 70 | female | 2 | 23 | 5.2 | 2 | alectinib 600 mg BID | 8.9 | true | MSS | 2026-03-15T05:35:57.988977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664697 | REC_0004622 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.1 | 58 | female | 0 | 19 | 6 | 6 | alectinib 600 mg BID | 5.2 | true | MSI-H | 2026-03-15T05:35:57.989212+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832733 | REC_0004623 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.9 | 73 | female | 1 | 75 | 6.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.6 | false | MSS | 2026-03-15T05:35:57.989442+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465010 | REC_0004624 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 12 | 71 | female | 1 | 6 | 5.8 | 5 | entrectinib 600 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:57.989675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499082 | REC_0004625 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 14.5 | 61 | male | 0 | 7 | 4.6 | 7 | alectinib 600 mg BID | 4 | true | MSI-H | 2026-03-15T05:35:57.989913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_632421 | REC_0004626 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 4.2 | 65 | female | 1 | 21 | 4.2 | 6 | pembrolizumab 200 mg q3w | 10.7 | false | MSS | 2026-03-15T05:35:57.990143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376294 | REC_0004627 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 13.5 | 67 | female | 1 | 8 | 5.8 | 1 | osimertinib 80 mg daily | 18.6 | false | MSI-H | 2026-03-15T05:35:57.990375+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_591117 | REC_0004628 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.9 | 60 | female | 1 | 15 | 6.1 | 2 | osimertinib 80 mg daily | 22.4 | false | MSS | 2026-03-15T05:35:57.990608+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768939 | REC_0004629 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.3 | 74 | female | 1 | 30 | 6.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 18.7 | true | MSS | 2026-03-15T05:35:57.990891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229674 | REC_0004630 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 9.1 | 55 | female | 0 | 17 | 4.1 | 7 | pembrolizumab 200 mg q3w | 6.6 | false | MSS | 2026-03-15T05:35:57.991127+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476552 | REC_0004631 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 19.8 | 53 | female | 0 | 2 | 6.7 | 8 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:57.991363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357511 | REC_0004632 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 17.3 | 85 | female | 2 | 9 | 5 | 5 | entrectinib 600 mg daily | 7.1 | true | MSI-H | 2026-03-15T05:35:57.991594+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244028 | REC_0004633 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 13.5 | 59 | male | 1 | 11 | 5.6 | 5 | sotorasib 960 mg daily | 6.4 | true | MSS | 2026-03-15T05:35:57.991828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389146 | REC_0004634 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 17.8 | 54 | male | 0 | 20 | 5 | 7 | osimertinib 80 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:57.992062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614750 | REC_0004635 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 10.8 | 70 | female | 2 | 14 | 7.1 | 6 | alectinib 600 mg BID | 8.3 | false | MSI-H | 2026-03-15T05:35:57.992345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_240707 | REC_0004636 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 12 | 73 | female | 1 | 12 | 7.1 | 6 | alectinib 600 mg BID | 15.4 | false | MSI-H | 2026-03-15T05:35:57.992581+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519908 | REC_0004637 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 3.3 | 67 | female | 0 | 16 | 6 | 1 | entrectinib 600 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:57.992815+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219591 | REC_0004638 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.6 | 65 | male | 0 | 29 | 6.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.2 | false | MSS | 2026-03-15T05:35:57.993044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587067 | REC_0004639 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.5 | 73 | female | 1 | 33 | 7.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.2 | true | MSS | 2026-03-15T05:35:57.993278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525918 | REC_0004640 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 4.7 | 69 | female | 0 | 17 | 6.2 | 8 | pembrolizumab 200 mg q3w | 5.8 | false | MSS | 2026-03-15T05:35:57.993507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323110 | REC_0004641 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 10 | 87 | female | 1 | 15 | 2.9 | 8 | entrectinib 600 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:35:57.993740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503523 | REC_0004642 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 10.2 | 77 | male | 2 | 18 | 3.5 | 6 | osimertinib 80 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:35:57.994027+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349977 | REC_0004643 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 6.3 | 72 | female | 1 | 12 | 5 | 5 | alectinib 600 mg BID | 14 | true | MSS | 2026-03-15T05:35:57.994259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422593 | REC_0004644 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 9.7 | 63 | male | 1 | 14 | 5.7 | 1 | osimertinib 80 mg daily | 20.5 | true | MSS | 2026-03-15T05:35:57.994489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573739 | REC_0004645 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 9.4 | 59 | male | 1 | 10 | 6.2 | 1 | entrectinib 600 mg daily | 19.3 | true | MSS | 2026-03-15T05:35:57.994722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_942630 | REC_0004646 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 16.2 | 83 | male | 2 | 15 | 5.2 | 1 | alectinib 600 mg BID | 23.6 | false | MSI-H | 2026-03-15T05:35:57.994958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753427 | REC_0004647 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 14.5 | 61 | male | 1 | 15 | 7.1 | 3 | entrectinib 600 mg daily | 5.8 | true | MSI-H | 2026-03-15T05:35:57.995194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165581 | REC_0004648 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 31 | 12.2 | 61 | male | 0 | 21 | 5.4 | 0 | entrectinib 600 mg daily | 50.9 | true | MSS | 2026-03-15T05:35:57.995428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823603 | REC_0004649 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 11.7 | 64 | male | 1 | 10 | 5.9 | 5 | sotorasib 960 mg daily | 12.7 | true | MSS | 2026-03-15T05:35:57.995672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248150 | REC_0004650 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 4.2 | 52 | female | 0 | 40 | 6 | 9 | carboplatin + paclitaxel + pembrolizumab | 5.2 | true | MSS | 2026-03-15T05:35:57.995912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413833 | REC_0004651 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 7 | 59 | female | 1 | 19 | 3.6 | 6 | pembrolizumab 200 mg q3w | 16.7 | true | MSS | 2026-03-15T05:35:57.996238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690944 | REC_0004652 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 16.2 | 64 | male | 1 | 20 | 5 | 8 | osimertinib 80 mg daily | 10 | false | MSI-H | 2026-03-15T05:35:57.996480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558472 | REC_0004653 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 15 | 68 | female | 1 | 1 | 5.6 | 6 | alectinib 600 mg BID | 11 | false | MSS | 2026-03-15T05:35:57.996720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655481 | REC_0004654 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 16.2 | 50 | female | 0 | 15 | 5.7 | 7 | osimertinib 80 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:57.996953+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685045 | REC_0004655 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 14.2 | 66 | female | 1 | 19 | 6.1 | 1 | osimertinib 80 mg daily | 5.9 | true | MSS | 2026-03-15T05:35:57.997248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765738 | REC_0004656 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 10.6 | 77 | female | 1 | 14 | 5.9 | 5 | entrectinib 600 mg daily | 11.2 | true | MSI-H | 2026-03-15T05:35:57.997484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681033 | REC_0004657 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 12.4 | 66 | female | 0 | 16 | 5.6 | 1 | sotorasib 960 mg daily | 5 | false | MSI-H | 2026-03-15T05:35:57.997719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122204 | REC_0004658 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 14 | 6.4 | 68 | female | 1 | 21 | 4 | 7 | alectinib 600 mg BID | 8.7 | false | MSS | 2026-03-15T05:35:57.997948+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503261 | REC_0004659 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.2 | 67 | female | 0 | 12 | 5.6 | 7 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:35:57.998180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369461 | REC_0004660 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 9.8 | 67 | female | 0 | 20 | 6.2 | 5 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:35:57.998406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422877 | REC_0004661 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 11.7 | 59 | male | 1 | 19 | 5.5 | 6 | osimertinib 80 mg daily | 13.6 | false | MSI-H | 2026-03-15T05:35:57.998640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846440 | REC_0004662 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13.3 | 76 | female | 2 | 2 | 4.2 | 5 | osimertinib 80 mg daily | 10.6 | true | MSI-H | 2026-03-15T05:35:57.998870+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106414 | REC_0004663 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 15.2 | 65 | female | 0 | 17 | 5.4 | 1 | osimertinib 80 mg daily | 15.7 | true | MSS | 2026-03-15T05:35:57.999110+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730468 | REC_0004664 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10.2 | 64 | male | 1 | 10 | 4.8 | 5 | alectinib 600 mg BID | 14.9 | false | MSI-H | 2026-03-15T05:35:57.999351+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742590 | REC_0004665 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 5.8 | 74 | female | 2 | 28 | 7.7 | 9 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.999581+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639987 | REC_0004666 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 7.1 | 82 | female | 0 | 18 | 5.4 | 1 | pembrolizumab 200 mg q3w | 12.7 | true | MSS | 2026-03-15T05:35:57.999810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843508 | REC_0004667 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 10.5 | 67 | female | 1 | 8 | 7.5 | 2 | sotorasib 960 mg daily | 18.8 | true | MSI-H | 2026-03-15T05:35:58.000052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184560 | REC_0004668 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 7 | 73 | female | 2 | 21 | 7.9 | 2 | alectinib 600 mg BID | 7.8 | false | MSS | 2026-03-15T05:35:58.000439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961500 | REC_0004669 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 12.6 | 66 | female | 1 | 15 | 5 | 6 | sotorasib 960 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:58.000703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673726 | REC_0004670 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 9.8 | 64 | male | 1 | 10 | 6.4 | 2 | entrectinib 600 mg daily | 18.3 | true | MSS | 2026-03-15T05:35:58.000945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739930 | REC_0004671 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 8.2 | 57 | female | 1 | 18 | 7.4 | 2 | entrectinib 600 mg daily | 20.9 | true | MSS | 2026-03-15T05:35:58.001197+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854236 | REC_0004672 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 9.2 | 54 | male | 0 | 19 | 6 | 4 | osimertinib 80 mg daily | 17.7 | true | MSS | 2026-03-15T05:35:58.001458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554223 | REC_0004673 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 19.3 | 57 | male | 1 | 10 | 3.6 | 3 | osimertinib 80 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:35:58.001714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659359 | REC_0004674 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 7 | 67 | female | 0 | 5 | 6.3 | 5 | entrectinib 600 mg daily | 13.1 | false | MSS | 2026-03-15T05:35:58.001952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606516 | REC_0004675 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 29 | 10.2 | 67 | male | 1 | 27 | 5.4 | 0 | osimertinib 80 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:58.002198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452739 | REC_0004676 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 10.6 | 65 | female | 0 | 23 | 2.9 | 1 | osimertinib 80 mg daily | 17.5 | false | MSS | 2026-03-15T05:35:58.002438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548078 | REC_0004677 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 8.1 | 58 | female | 0 | 10 | 5.8 | 1 | alectinib 600 mg BID | 12.1 | false | MSS | 2026-03-15T05:35:58.002674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358780 | REC_0004678 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 9.4 | 70 | female | 1 | 42 | 7.1 | 1 | pembrolizumab 200 mg q3w | 30.9 | false | MSS | 2026-03-15T05:35:58.002905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324869 | REC_0004679 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 9.4 | 66 | female | 0 | 8 | 3.9 | 3 | sotorasib 960 mg daily | 9.2 | true | MSS | 2026-03-15T05:35:58.003140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572116 | REC_0004680 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 10.1 | 68 | female | 1 | 9 | 5.9 | 5 | entrectinib 600 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:35:58.003371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560891 | REC_0004681 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 11.9 | 68 | female | 0 | 22 | 6.9 | 2 | sotorasib 960 mg daily | 13.3 | false | MSI-H | 2026-03-15T05:35:58.003718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895290 | REC_0004682 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 7.5 | 62 | female | 0 | 61 | 4.2 | 4 | pembrolizumab 200 mg q3w | 14.3 | false | MSS | 2026-03-15T05:35:58.003966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865893 | REC_0004683 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 16.2 | 70 | female | 0 | 22 | 5.9 | 7 | osimertinib 80 mg daily | 14.6 | false | MSI-H | 2026-03-15T05:35:58.004283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401324 | REC_0004684 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 3.4 | 66 | female | 1 | 56 | 4.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.5 | false | MSS | 2026-03-15T05:35:58.004526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554919 | REC_0004685 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 11.7 | 65 | female | 0 | 23 | 6.1 | 4 | osimertinib 80 mg daily | 10.1 | true | MSI-H | 2026-03-15T05:35:58.004774+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796742 | REC_0004686 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 17.6 | 66 | female | 0 | 10 | 6.5 | 3 | pembrolizumab 200 mg q3w | 22.1 | false | MSI-H | 2026-03-15T05:35:58.005012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_921655 | REC_0004687 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 6.7 | 65 | female | 0 | 6 | 4.6 | 6 | osimertinib 80 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:58.005245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419923 | REC_0004688 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 15.7 | 72 | female | 1 | 25 | 4 | 2 | entrectinib 600 mg daily | 21.7 | true | MSI-H | 2026-03-15T05:35:58.005479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915051 | REC_0004689 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 4.8 | 64 | female | 0 | 18 | 8.2 | 4 | osimertinib 80 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:58.005713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_484450 | REC_0004690 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 3.8 | 57 | male | 0 | 46 | 6.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.5 | false | MSS | 2026-03-15T05:35:58.005947+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162326 | REC_0004691 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 21 | 14.8 | 72 | female | 2 | 21 | 6.4 | 0 | osimertinib 80 mg daily | 52.3 | false | MSS | 2026-03-15T05:35:58.006183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593813 | REC_0004692 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 9.5 | 75 | male | 3 | 21 | 6.9 | 7 | osimertinib 80 mg daily | 17.7 | true | MSS | 2026-03-15T05:35:58.006430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986427 | REC_0004693 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 9.5 | 69 | female | 0 | 13 | 3.8 | 1 | alectinib 600 mg BID | 12.3 | false | MSS | 2026-03-15T05:35:58.006670+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512526 | REC_0004694 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 14.1 | 87 | female | 2 | 17 | 5.9 | 2 | alectinib 600 mg BID | 26.4 | false | MSS | 2026-03-15T05:35:58.007030+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331498 | REC_0004695 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 4.3 | 74 | male | 2 | 15 | 5.1 | 1 | sotorasib 960 mg daily | 15.3 | false | MSS | 2026-03-15T05:35:58.007295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843302 | REC_0004696 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 4 | 75 | female | 2 | 17 | 4.7 | 6 | alectinib 600 mg BID | 11.7 | true | MSS | 2026-03-15T05:35:58.007549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648487 | REC_0004697 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 6.7 | 58 | male | 0 | 19 | 6.1 | 5 | pembrolizumab 200 mg q3w | 11.2 | false | MSS | 2026-03-15T05:35:58.007801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880815 | REC_0004698 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 4.8 | 63 | female | 1 | 56 | 5.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.7 | false | MSS | 2026-03-15T05:35:58.008050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787313 | REC_0004699 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 28 | 14 | 79 | male | 1 | 6 | 6 | 0 | alectinib 600 mg BID | 34.3 | false | MSS | 2026-03-15T05:35:58.008360+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278660 | REC_0004700 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 13 | 64 | female | 0 | 16 | 6.3 | 2 | osimertinib 80 mg daily | 21.4 | false | MSI-H | 2026-03-15T05:35:58.008603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.